{"lc": 1, "type": "constructor", "id": ["langchain", "schema", "document", "Document"], "kwargs": {"page_content": "The provided image is a schematic representation illustrating the role of HELLS (Helicase, Lymphoid Specific) in cell cycle regulation and retinoblastoma development.\n\n**Panel A: Normal Condition**\n- **RB/p107 (Retinoblastoma protein/p107)** is shown binding to **E2F1**, a transcription factor, which represses the expression of **HELLS**.\n- This repression leads to no HELLS expression after postnatal day 6 (P6) in the developing retina, indicating a controlled cell cycle and normal retinal development.\n\n**Panel B: Pathological Condition**\n- The absence or reduction of RB/p107 allows **E2F1** to activate the expression of **HELLS**.\n- HELLS, in turn, interacts with another transcription factor, **E2F3**.\n- This interaction activates the expression of cell cycle genes such as **PCNA (Proliferating Cell Nuclear Antigen), CDC6 (Cell Division Cycle 6), and E2F1** itself.\n- The activation of these genes leads to ectopic (abnormal) cell proliferation.\n- This uncontrolled proliferation can result in the development of **retinoblastoma**, a type of eye cancer.\n\nOverall, the image emphasizes the importance of RB/p107 in regulating HELLS expression through E2F1 to prevent abnormal cell proliferation and retinoblastoma.", "metadata": {"source": "./documents/UC Irvine/JW_Dissertation_20220824.pdf", "image_path": "./extracted_images/UC Irvine/JW_Dissertation_20220824/figure-133-25.jpg"}, "type": "Document"}}